Trending: Impact of Senator Cassidy’s Draft PATIENT AI Act on Healthcare and AI

On October 29, 2026, Senator Bill Cassidy (R-LA), Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, released a legislative discussion draft of the PATIENT AI Act. The proposal aims to modernize healthcare AI oversight while protecting patient privacy and security.

The proposed legislation would:

  • Direct HHS to strengthen its internal AI processes and address patient privacy and security.

  • Clarify when AI technologies fall under FDA oversight.

  • Give the FDA new authority to review software on a rolling basis.

  • Establish a payment pathway to support adoption of AI-based tools.

Senator Cassidy is requesting stakeholder feedback by December 1, 2026. Comments can be sent to patientai@help.senate.gov.

Read the PATIENT AI Act Discussion Draft.

What could this mean for patients, healthcare providers, and clinical laboratories?

  • Could the legislation accelerate adoption of AI tools that improve diagnostic capabilities and patient access?

  • Would clearer regulatory oversight improve the safety and efficacy of AI products?

  • Could new reimbursement pathways encourage healthcare organizations to integrate AI into clinical workflows?

Anne TateComment
Leading During Turbulent Times

Healthcare and laboratory leaders are navigating an increasingly complex environment. Disruptive technologies, reimbursement realignment, regulatory uncertainty, Medicaid reductions, and evolving consumer expectations are reshaping how laboratories operate and deliver value. The pace of change is accelerating, making it increasingly difficult for laboratories to adapt while maintaining financial and operational stability.

Dr. William Morice II, president and CEO of Rochester, Minn.-based Mayo Clinic Laboratories, offers an important perspective on leading through this uncertainty. His recommendation: adopt a strategic response to disruption rather than reacting to every new development.

That means staying informed, evaluating emerging trends against organizational priorities, planning for multiple possible outcomes, experimenting before making major investments, and developing the workforce capabilities needed to support future growth.

For laboratory leaders, the distinction is important. Success will depend not simply on keeping pace with change, but on determining which changes matter most, where to invest resources, and how to position the laboratory for long-term relevance and value.

This is an excellent read for laboratory leaders thinking about how to navigate the next era of healthcare transformation.

Anne TateComment
PAMA Clinical Lab Fee Schedule for 2027 based on Incomplete Data

The 2027 Clinical Lab Fee Schedule will be based on 2 percent of reporting laboratories.

The proposed rates would reduce payment for almost 1,200 tests, including 775 tests that would face the maximum 15 percent cut in 2027, followed by additional reductions in 2028 and 2029.

See the article from ACLA

Preliminary Medicare Laboratory Rates Based on Incomplete Data Underscore Urgent Need for the RESULTS Act - American Clinical Laboratory Association

Anne TateComment